Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725387 · ClinicalTrials.gov registry record
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
A clinical trial of Neoplasms, sponsored by Stanford University.
- Completed
- Registry status
- 214
- Enrollment target
- 5
- Study locations
NCT00725387: Completed study of Neoplasms, sponsored by Stanford University.
NCT00725387 is a study of Neoplasms that has completed, run by Stanford University. The registered enrollment target is 214 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725387, a study of Neoplasms, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 214 participants
- Enrollment target
- 5
- Study locations
Study Summary
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.
Conditions Studied
Study Locations (5)
Other
- Aalborg Hospital - Aalborg
- Apollo Hospital - Chennai
- Coimbra University Hospital - Coimbra
- Pretoria Academic Hospital - Pretoria
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2007-08 |
| Est. Completion | 2019-06 |
What the finished NCT00725387 record still lists
NCT00725387 is an observational study that tracks outcomes without assigning an intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT00725387 lists 5 locations in 2 states (Other, California).
Frequently Asked Questions
What is clinical trial NCT00725387 about?
NCT00725387 is a clinical study titled "Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy". Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administ...
What is the current status of trial NCT00725387?
This trial is currently completed. The enrollment target is 214 participants. The study started on 2007-08. Estimated completion is 2019-06.
What conditions does trial NCT00725387 study?
This clinical trial studies the following conditions: Neoplasms.
Who is sponsoring clinical trial NCT00725387?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00725387 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00725387's enrollment target sits among peer trials
214 47th of 158 higher than 112 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia